12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Basilea, J&J sales and marketing update

In June, CHMP of the European Medicines Agency (EMA) issued a second negative opinion for an MAA, while FDA issued a second complete response letter last December for an NDA for the broad spectrum anti-MRSA cephalosporin antibiotic. Basilea is in arbitration with J&J over the pharma's mishandling...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >